Equities research analysts expect that Amyris Inc (NASDAQ:AMRS) will post earnings per share of ($0.30) for the current quarter, Zacks reports. Two analysts have issued estimates for Amyris’ earnings. The highest EPS estimate is ($0.29) and the lowest is ($0.30). Amyris posted earnings of ($1.36) per share in the same quarter last year, which suggests a positive year over year growth rate of 77.9%. The firm is expected to announce its next quarterly earnings results after the market closes on Monday, August 6th.
According to Zacks, analysts expect that Amyris will report full year earnings of ($1.92) per share for the current financial year, with EPS estimates ranging from ($1.98) to ($1.85). For the next financial year, analysts forecast that the firm will post earnings of $0.20 per share, with EPS estimates ranging from $0.16 to $0.24. Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Amyris.
Amyris (NASDAQ:AMRS) last posted its quarterly earnings results on Monday, May 14th. The biotechnology company reported ($1.79) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.48) by ($1.31). The firm had revenue of $23.00 million for the quarter, compared to analysts’ expectations of $24.12 million. During the same quarter last year, the firm posted ($0.13) EPS. The firm’s revenue was up 77.2% on a year-over-year basis.
A number of equities research analysts have recently commented on AMRS shares. HC Wainwright set a $15.00 price target on shares of Amyris and gave the company a “buy” rating in a report on Friday, May 25th. BidaskClub cut shares of Amyris from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 17th. Zacks Investment Research cut shares of Amyris from a “hold” rating to a “strong sell” rating in a report on Monday, June 4th. ValuEngine cut shares of Amyris from a “buy” rating to a “hold” rating in a report on Friday, June 1st. Finally, B. Riley set a $10.00 price target on shares of Amyris and gave the company a “buy” rating in a report on Tuesday, May 29th. Two investment analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. Amyris currently has an average rating of “Buy” and a consensus target price of $9.13.
In related news, major shareholder (Mauritius) Pte Ltd Maxwell sold 95,162 shares of the firm’s stock in a transaction that occurred on Monday, May 7th. The shares were sold at an average price of $6.54, for a total value of $622,359.48. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider John Melo sold 22,355 shares of the firm’s stock in a transaction that occurred on Monday, July 16th. The stock was sold at an average price of $6.61, for a total transaction of $147,766.55. Following the completion of the sale, the insider now owns 748,908 shares in the company, valued at approximately $4,950,281.88. The disclosure for this sale can be found here. Corporate insiders own 21.80% of the company’s stock.
Hedge funds have recently modified their holdings of the stock. Dynamic Technology Lab Private Ltd purchased a new stake in Amyris in the first quarter worth approximately $110,000. Element Capital Management LLC purchased a new stake in Amyris in the first quarter worth approximately $227,000. B. Riley Financial Inc. purchased a new stake in Amyris in the first quarter worth approximately $294,000. Tibra Equities Europe Ltd purchased a new stake in Amyris in the first quarter worth approximately $295,000. Finally, Barclays PLC boosted its holdings in Amyris by 30,067.8% in the first quarter. Barclays PLC now owns 44,950 shares of the biotechnology company’s stock worth $300,000 after purchasing an additional 44,801 shares during the last quarter. Institutional investors own 23.65% of the company’s stock.
Shares of NASDAQ:AMRS traded down $0.07 during trading on Tuesday, reaching $6.87. 355,823 shares of the stock traded hands, compared to its average volume of 481,310. Amyris has a 52-week low of $1.86 and a 52-week high of $7.30. The company has a current ratio of 0.67, a quick ratio of 0.62 and a debt-to-equity ratio of -0.35.
Amyris Company Profile
Amyris, Inc provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market.
Read More: Earnings Per Share
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.